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Interferon Lambda 4 Variant rs12979860 Is Not Associated
With RAV NS5A Y93H in Hepatitis C Virus Genotype 3a
TO THE EDITOR:
Peiffer et al. recently reported(1) an association
between the host interferon lambda 4 (INFL4) single-
nucleotide polymorphism (SNP), rs12979860, and the
NS5A resistance-associated variant (RAV) Y93H in
hepatitis C virus (HCV) genotype 1b (HCVg1b). This
observation is intriguing because it directly links innate
immunity to HCV viral drug resistance for the ﬁrst
time. A small cohort of (51) HCV genotype 3
(HCVg3) patients was included in the analysis; this
subgroup analysis was underpowered and no associa-
tion was observed in HCVg3. The association was also
not observed in 259 patients with HCV subtype 1a.
HCVg3 infections are more difﬁcult to treat with
direct-acting antivirals. The reason for this is un-
known, but could be explained by a distinct pattern of
RAVs and an increase in the prevalence of “favorable”
IFNL4 SNPs in this genotype. Here, we used a large
cohort of 496 HCVg3a-infected patients (from the
BOSON clinical study(2)) and report no signiﬁcant
association (P> 0.05) between the treatment-
beneﬁcial C/C genotype of INFL4 and RAV site
Y93H in the NS5A gene.
Using next-generation sequencing,(3) baseline viral
sequences from 556 BOSON patients chronically
infected with either HCVg2 or HCVg3 were obtained.
The INFL4 SNP rs12979860 was also genotyped. The
cohort (total of 556) was composed of 49 (8.8%)
HCVg2- and 507 (91.2%) HCVg3-infected patients,
of which 496 (89.2%) were subtype 3a.
Substitutions in the quasi-species at Y93 (Y93H)
were only observed in HCVg3a-infected patients;
therefore, the analysis was done on this subset of the
data. The Y93H RAV was present in 11.1% (55 of
496) of the genotype 3a–infected patients; in 4.7% (23
of 496), Y93H was as the majority variant. There was
no signiﬁcant association between the presence of H
(either as the consensus level or at any level of detec-
tion) and the beneﬁcial C/C genotype of INFL4
(P> 0.05; Table 1). Overall, our data support the
Peiffer et al. hypothesis that the association between
INFL4 and Y93H is speciﬁc to HCV genotype 1b.
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TABLE 1. Prevalence of Y93H RAV in HCVg3a-Infected
Patients (n5496) Stratified by rs12979860 IFNL4 SNP
Y93H: Consensus
Level n/N (%)
Y93H: All Types
n/N (%)
INFL4 C/C 12/184 (6.5) 25/184 (13.5)
INFL4 non C/C 11/312 (3.5) 30/312 (9.6) Author names in bold designate shared co-first authorship.
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